AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25237
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg etilefrin
Trial: 25237
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg dihydroergotamine
Trial: 31429006
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate (1500 mg once/day) in addition to conventional therapy
Trial: 25284704
Drug: Clonidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (150 μg oral dose) with STN‐DBS ON
Trial: 25284704
Drug: Clonidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (150 μg oral dose) with STN‐DBS OFF
Trial: 16902083
Drug: Hospital clinic-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital clinic-based chemotherapy
Trial: 11130089
Drug: Dinoproston, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoproston, 0.5 mg intracervically every 12 hours for a maximum of 24 hours
Trial: 8339645
Drug: Magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium infusion (6 g MgSO4 i.v. over 16 h)
Trial: 3732368
Drug: Twice-daily administration
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily administration of beclomethasone dipropionate aerosol
Trial: 3732368
Drug: Four-times daily
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-times daily administration of beclomethasone dipropionate aerosol
Trial: 22326841
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 60 mg/day
Trial: 18616516
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (PPI) regimen
Trial: 12428223
Drug: Anakinra (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (30, 75, or 150 mg) once daily
Trial: 9506875
Drug: Meloxicam 30
RxNorm normalized name: meloxicam 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 30 mg
Trial: 28719227
Drug: Simvastatin (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20-40 mg/day)
Trial: 27467969
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of discharge BNP ≤319pg/mL and percentage BNP reduction ≥7.71%
Trial: 25200142
Drug: Clopidogrel with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel with Aspirin followed by Clopidogrel
Trial: 20654757
Drug: Pharmacy-administered DMPA-SC
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacy-administered DMPA-SC
Trial: 20654757
Drug: Clinic-administered DMPA-SC
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-administered DMPA-SC
Trial: 12434893
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (2.5 mmol/L serum Mg2+)
Trial: 8936959
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human growth hormone (GH) 15 U/m2/week for 1 year (Groups (I)b, (II)a, (III)b)
Trial: 8936959
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (both doses) for 1 year
Trial: 8936959
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (Group (III))
Trial: 1656741
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg on day 1, followed by 250 mg/day on days 2-5)
Trial: 1656741
Drug: Cephalexin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (500 mg twice daily for 10 days)
Trial: 20092407
Drug: Primary vaccination
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary vaccination with 23-valent pneumococcal polysaccharide vaccine (PN23)
Trial: 20092407
Drug: Revaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23)
Trial: 20092407
Drug: Serotype 3
RxNorm normalized name: HUMAN ADENOVIRUS B SEROTYPE 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotype 3 antibody levels
Trial: 17906203
Drug: Adjuvant fluorouracil-based
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant fluorouracil-based chemotherapy (CT)
Trial: 11895063
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor and beta-blocker therapy
Trial: 9798584
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate 40 mg or 80 mg
Trial: 9798584
Drug: Gemeprost 1
RxNorm normalized name: Gemeprost 1 mg vaginal pessary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemeprost 1 mg
Trial: 7865646
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 800 mg 5-ASA
Trial: 7865646
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral dose of 2400 mg/day for 56 days of 5-ASA
Trial: 2645553
Drug: Levobunolol 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobunolol 0.5% once-daily treatment
Trial: 2645553
Drug: Levobunolol 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobunolol 0.5% twice-daily treatment
Trial: 29534902
Drug: No postmastectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postmastectomy radiation therapy (no-PMRT)
Trial: 29534902
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with no taxane
Trial: 29534902
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with no taxane (no-PMRT)
Trial: 10910026
Drug: Immunoadsorption (IA)
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoadsorption (IA) performed on 5 consecutive days using an adsorber against immunoglobulins (Ig Therasorb, Baxter) with substitution of 0.5 g/kg of polyclonal immunoglobulin after the final session
Trial: 1353386
Drug: Prazosin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 3 mg b.d. for 2 weeks
Trial: 6584389
Drug: 3 X
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 100 mg oxyphenbutazone daily
Trial: 22764337
Drug: Perifacet injection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifacet injection into the lumbar multifidus muscle with methylprednisolone
Trial: 20142346
Drug: Bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2.5 mg/mL, 20 mL given every third hour for 72 hours postoperatively.
Trial: 15827103
Drug: Calcium (1
RxNorm normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1 g/d)
Trial: 12479545
Drug: Artesunate (4-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, approximately 8.5 mg/kg/day) given simultaneously for three days
Trial: 12479545
Drug: Artesunate (4-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, sequentially administered)
Trial: 12479545
Drug: Artesunate (4-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, simultaneously)
Trial: 12479545
Drug: Artesunate (4-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, sequentially)
Trial: 12479545
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (sequential)
Trial: 9497660
Drug: Acuhealth treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acuhealth treatment (group A)
Trial: 9497660
Drug: Occlusal splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal splint therapy (group B)
Trial: 9497660
Drug: Acuhealth and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acuhealth and occlusal splint therapy (group C)
Trial: 2104736
Drug: Nitroglycerin 0.8
RxNorm normalized name: nitroglycerin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin 0.8 mg spray
Trial: 30453910
Drug: Ruxolitinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib and best available treatment (BAT)
Trial: 28369188
Drug: Postoperative self
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative self administration of intra‐venous analgesia by patients
Trial: 16192577
Drug: Bec2 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bec2 (2.5 mg)/BCG vaccine
Trial: 16192577
Drug: Bec2/BCG vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bec2/BCG vaccine (among vaccinated patients)
Trial: 364626
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg prednisolone once daily (single dose)
Trial: 364626
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg prednisolone four times a day (divided doses)
Trial: 31446990
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine and cisplatin (OVP)
Trial: 27140800
Drug: Lapatinib powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib powder for oral suspension
Trial: 27140800
Drug: Commercial tablet
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial tablet formulation of lapatinib
Trial: 23916965
Drug: Web-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cognitive behavioral therapy (CBT) with therapist support for 6 weeks using the MoodGYM program.
Trial: 21810677
Drug: MVAC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVAC chemotherapy (methotrexate, vinblastine, doxorubicin, and cisplatin) for three cycles
Trial: 19803020
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chlorpheniramine plus chloroquine (6 mg + 12 mg/day for 7 days in children ≤ 5 years; 8 mg + 18 mg/day for 7 days in those >5 years) plus chloroquine 10 mg/kg daily for 3 days
Trial: 19803020
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose chlorpheniramine plus chloroquine (50% higher dose) plus chloroquine 10 mg/kg daily for 3 days
Trial: 17268417
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group supplemented daily with 6 mg lutein combined with vitamins and minerals.
Trial: 9457393
Drug: recombinant interleukin‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant interleukin‐2 (rIL‐2) therapy (8‐18 x 10(6) IU/m2 x 5 days) by continuous intravenous infusion with a 72‐hour rest period between each cycle, followed by subcutaneous maintenance rIL‐2 therapy at lower doses for 5 days/month
Trial: 9457393
Drug: rIL‐2 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIL‐2 therapy
Trial: 3129390
Drug: Enoxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin (400 mg bd)
Trial: 3129390
Drug: Amoxycillin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (1,000 mg tid)
Trial: 30134549
Drug: Natural dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural dietary supplement (NDS) containing Curcuma longa, silymarin, guggul, chlorogenic acid and inulin
Trial: 25776067
Drug: OPT-CON therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPT-CON therapy (Optimised concomitant therapy) - esomeprazole (40 mg b.d.), amoxicillin (1 g b.d.), clarithromycin (500 mg b.d.), and metronidazole (500 mg b.d.) for 14 days
Trial: 25776067
Drug: OPT-TRI therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPT-TRI therapy (Optimised triple therapy) - esomeprazole (40 mg b.d.), amoxicillin (1 g b.d.), and clarithromycin (500 mg b.d.) for 14 days
Trial: 25776067
Drug: OPT-CON therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPT-CON therapy
Trial: 25776067
Drug: OPT-TRI therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPT-TRI therapy
Trial: 23574458
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g tranexamic acid intravenously over 10 min before elective cesarean section
Trial: 19134445
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care treatment with no bands
Trial: 15059051
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment as determined by ward staff (223 patients)
Trial: 11481298
Drug: Piperacillin-tazobactam 6.0/0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam 6.0/0.75 g q12h
Trial: 11481298
Drug: Piperacillin-tazobactam 8.0/1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam 8.0/1.0 g q12h
Trial: 8149358
Drug: half the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: half the dose of ME together with a halved tablet of Sinemet CR
Trial: 29956199
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (active treatment), 8 sessions of 5 minutes each over 4 weeks
Trial: 24785885
Drug: Kakkonto Extract‐A,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kakkonto Extract‐A, 6 g/day
Trial: 24785885
Drug: Pabron Gold‐A,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pabron Gold‐A, 3.6 g/day
Trial: 16228839
Drug: Subcutaneous gentamycin-collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous gentamycin-collagen implant
Trial: 16228839
Drug: Collagen implant
RxNorm normalized name: Collagen implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen implant without antibiotics (placebo)
Trial: 9129563
Drug: Oral codeine
RxNorm normalized name: codeine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral codeine administration
Trial: 9129563
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo administration
Trial: 9129563
Drug: Pharmacokinetic parameters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic parameters of morphine
Trial: 23585559
Drug: Prednisolone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (20 mg for 6 weeks, 10 mg for 1 week, 5 mg for 1 week)
Trial: 19139319
Drug: Vasopressin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin (20 IU per CPR cycle) plus epinephrine (1 mg per CPR cycle)
Trial: 19139319
Drug: Stress-dose hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Stress-dose hydrocortisone sodium succinate (300 mg daily for 7 days maximum)
Trial: 19139319
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride solution placebo plus epinephrine (1 mg per CPR cycle)
Trial: 9203725
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral poliovirus vaccine (OPV) administered in the rainy season
Trial: 9203725
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral poliovirus vaccine (OPV) administered in other seasons
Trial: 8278816
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (auranofin and methotrexate)
Trial: 24726174
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (500 mg)
Trial: 24726174
Drug: Joint irrigation
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint irrigation with TXA (3 g in 100 cc saline)
Trial: 24726174
Drug: TXA injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA injection through the drain (1.5 g)
Trial: 21422238
Drug: AR9281 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR9281 (250 mg)
Trial: 21422238
Drug: AR9281 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR9281 (500 mg)
Trial: 21422238
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of AR9281 (100-400 mg every 8 hours)
Trial: 18242008
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch and nicotine gum
Trial: 16183617
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of total score from the 16-item test with digits forward span
Trial: 16183617
Drug: Any single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any single test score or any other combination of digit span score with a Rey score
Trial: 12544991
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin (500 mg)
Trial: 30068817
Drug: Alirocumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75 mg every 2 weeks, increased to 150 mg if week 8 LDL-C was above predefined limits)
Trial: 29294360
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 μg once-daily
Trial: 19606092
Drug: Transdermal melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal melatonin (MEL) delivery during daytime
Trial: 19606092
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin (MEL)
Trial: 15353873
Drug: Eprosartan (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (400-800 mg daily)
Trial: 15353873
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose eprosartan or enalapril
Trial: 11593101
Drug: Irbesartan (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150-300 mg once daily)
Trial: 7988779
Drug: Sitostanol ester
RxNorm normalized name: disodium ascorbyl sitostanol phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitostanol ester (3 g daily)
Trial: 2594908
Drug: Pentobarbital (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital (30 mg per dose)
Trial: 31325604
Drug: Non-Chinese herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Chinese herbal medicine (non-CHM)
Trial: 24144896
Drug: GSK1265744 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 (5 mg)
Trial: 24144896
Drug: GSK1265744 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 (30 mg)
Trial: 8996851
Drug: Piperacillin (PPR)
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin (PPR) 60 mg/kg infusion every 8 hours
Trial: 8996851
Drug: Modified dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified dosage pattern of Piperacillin (PPR) 60 mg/kg every 4 hours
Trial: 1444872
Drug: Diltiazem (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180 mg for the first 48 hours, adjusted to 240 mg until the 7th day)
Trial: 1444872
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 mg for the first 48 hours, adjusted to 160 mg until the 7th day)
Trial: 30429357
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of semaglutide coformulated with sodium N‐[8‐(2‐hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.
Trial: 30429357
Drug: SNAC as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNAC as an absorption enhancer.
Trial: 24286335
Drug: GSK315234 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK315234 3 mg/kg
Trial: 24286335
Drug: GSK315234 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK315234 0.3 mg/kg
Trial: 24286335
Drug: GSK315234 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK315234 6 mg/kg
Trial: 24286335
Drug: GSK315234 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK315234 500 mg subcutaneous
Trial: 16988537
Drug: Xanax XR
RxNorm normalized name: Xanax XR
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xanax XR 1 mg
Trial: 16988537
Drug: Xanax XR
RxNorm normalized name: Xanax XR
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xanax XR 3 mg